Skip to main content
. 2017 Feb 9;64(5):621–628. doi: 10.1093/cid/ciw833

Table 3.

Bi- and Multivariate Analysis of Validation Cohort

Factor LTNP-C (n = 242) Non-LTNP-C (n = 222) P; OR (95% CI) P; OR (95% CI)
Unadjusted Adjusted
Sex (male) 197 (81.4) 183 (82.1) .774; .933 (.581–1.498)
Age at HIV diagnosis (years) 32 (26–38) 35 (29–41) .001; .965 (.945–.985) .001; .962 (.942–.983)
Interferon-lambda 4 A/A genotype 103 (42.6) 121 (54.3) .012; .625 (.433–.901) .021; .637 (.434–.934)
HLA-B*27a 53 (22.3) 38 (17.9) .253; 1.312 (.824–2.089)
HLA-B*57a 84 (35.3) 47 (22.2) .002; 1.915 (1.259–2.912) .03; 1.924 (1.252–2.957)
HLA-B*35a 23 (9.7) 22 (10.4) .801; .924 (.499–1.711)
HLA-B*08a 23 (9.7) 26 (12.3) .378; .765 (.422–1.387)

Qualitative data are number (%) of individuals and quantitative data are median (interquartile range). Significant values are shown in bold.

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; LTNP-C, long-term nonprogressor HIV-1 controller; OR, odds ratio.

aDominant model was applied. There were only 3 homozygous patients for HLA-B*57.